Key Takeaways
- Generic industry stakeholders worry US tariffs on China and potentially other countries could further stress the generic drug industry.
- AAM CEO John Murphy III said the new Trump Administration also presents opportunities to advocate for policy and legislative reforms.
- Rhetoric about on-shoring US manufacturing likely will not translate to tangible policy, experts said.
While the Association for Accessible Medicines’ Access! 2025 meeting represented the generics and biosimilars group’s first annual conference with its
Immediately after a weekend that saw Trump cause global upheaval with threats of immediate tariffs on Canada, Mexico and China, as well as potential tariffs on the EU, attendees to the AAM event in Amelia Island, FL, heard Murphy’s views on the risks the
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?